Search results for CD20

Anti-Human CD20/MS4A1 Antibody (SAA2209), FITC (HY257617), abinScience, HY257617

Anti-Human CD20/MS4A1 Antibody (SAA2210), PerCP (HY257747), abinScience, HY257747

Anti-Human CD20/MS4A1 Antibody (2H7), PerCP (HY257447), abinScience, HY257447

Anti-Mouse CD20/MS4A1 Antibody (18B12), APC (MY257137), abinScience, MY257137

Anti-Human CD20/MS4A1 Antibody (SAA2210), APC (HY257737), abinScience, HY257737

Anti-Mouse CD20/MS4A1 Antibody (18B12), FITC (MY257117), abinScience, MY257117

Anti-Human CD20/MS4A1 Antibody (SAA2208), PerCP (HY257547), abinScience, HY257547

Anti-Human CD20/MS4A1 Antibody (SAA0006), PE (HY257127), abinScience, HY257127

Epcoritamab Biosimilar – Anti-CD3E;MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1587

Description of Epcoritamab Biosimilar - Anti-CD3E;MS4A1, CD20 mAb - Research Grade Introduction Epcoritamab Biosimilar is a novel monoclonal antibody (mAb) that targets three important proteins, namely CD3E, MS4A1, and CD20. This biosimilar is being developed as a potential treatment for various diseases, including autoimmune disorders, cancer, and inflammatory conditions. In this article, we will provide a detailed scientific description of Epcoritamab Biosimilar, including its structure, activity, and potential applications. Structure of Epcoritamab Biosimilar Epcoritamab Biosimilar is a chimeric monoclonal antibody, meaning it is composed of both human and non-human components. The antibody is made up of two parts – a constant region and a variable region. The constant region is derived from human antibodies, while the variable region is derived from non-human sources, such as mice or rats. This structure allows Epcoritamab Biosimilar to bind to its target proteins with high specificity and affinity. The constant region of Epcoritamab Biosimilar is responsible for the effector functions of the antibody, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). These effector functions play a crucial role in the antibody’s ability to eliminate target cells. Activity of Epcoritamab Biosimilar Epcoritamab Biosimilar targets three key proteins – CD3E, MS4A1, and CD20. CD3E is a protein that is found on the surface of T cells, a type of immune cell that plays a crucial role in the body’s immune response. MS4A1, also known as CD20, is a protein found on the surface of B cells, another type of immune cell involved in the immune response. CD20 is also expressed on the surface of certain cancer cells, making it an attractive therapeutic target. Epcoritamab Biosimilar binds to CD3E and CD20 on the surface of T and B cells, respectively, leading to the activation of these cells. This activation triggers a cascade of events that ultimately results in the destruction of the target cells. Additionally, Epcoritamab Biosimilar also binds to MS4A1 on the surface of cancer cells, leading to their destruction. Applications of Epcoritamab Biosimilar Epcoritamab Biosimilar has several potential applications in the field of medicine. Its ability to target CD3E and CD20 makes it a promising candidate for the treatment of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. By targeting these proteins, Epcoritamab Biosimilar can suppress the activity of T and B cells, which are responsible for the development of these disorders. Furthermore, Epcoritamab Biosimilar has shown promising results in the treatment of various types of cancer. By targeting CD20 on the surface of cancer cells, Epcoritamab Biosimilar can induce their destruction, leading to tumor regression. It has shown particular efficacy in the treatment of B-cell malignancies, such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In addition to its therapeutic applications, Epcoritamab Biosimilar also has potential uses in research and diagnostic settings. Its ability to specifically target CD3E, MS4A1, and CD20 makes it a valuable tool for studying the functions of these proteins and their role in various diseases. Conclusion In conclusion, Epcoritamab Biosimilar is a chimeric monoclonal antibody that targets CD3E, MS4A1, and CD20. Its unique structure and activity make it a promising candidate for the treatment of autoimmune disorders and various types of cancer. Additionally, its potential uses in research and diagnostics make it a valuable tool for further understanding the functions of these proteins. With ongoing research and development, Epcoritamab Biosimilar has the potential to improve the lives of patients suffering from these diseases.

Mosunetuzumab Biosimilar – Anti-CD3E, MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1482

Description of Mosunetuzumab Biosimilar - Anti-CD3E, MS4A1, CD20 mAb - Research Grade The Structure of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is a monoclonal antibody (mAb) that specifically targets three proteins – CD3E, MS4A1, and CD20. It is a biosimilar version of the original Mosunetuzumab, which was developed by Genentech and is currently in clinical trials for the treatment of non-Hodgkin’s lymphoma. The biosimilar version is being developed by a different pharmaceutical company and is intended for research purposes only. The structure of Mosunetuzumab Biosimilar is similar to that of the original Mosunetuzumab, with a few minor differences. It is a humanized IgG1 antibody, meaning that it is derived from human antibodies and has been modified to reduce immunogenicity. It consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the target proteins, while the constant region is responsible for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The Activity of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is a bispecific antibody, meaning that it can bind to two different proteins at the same time. It binds to CD3E on T cells and MS4A1 on B cells, bringing these two cell types into close proximity. This leads to the activation of T cells, which then release cytokines and other molecules that help to kill the targeted B cells. In addition, Mosunetuzumab Biosimilar also binds to CD20 on B cells, triggering their death through ADCC and CDC. The ability of Mosunetuzumab Biosimilar to target multiple proteins and activate different immune mechanisms makes it a promising therapeutic option for the treatment of various B cell malignancies. It has shown particularly promising results in the treatment of non-Hodgkin’s lymphoma, where it has demonstrated high response rates in clinical trials. The Application of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is currently being developed for research purposes only and is not yet approved for clinical use. However, it has the potential to be used as a therapeutic agent for the treatment of various B cell malignancies, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. In addition to its potential as a monotherapy, Mosunetuzumab Biosimilar also has the potential to be used in combination with other therapies, such as chemotherapy or other targeted therapies. Its bispecific nature and ability to activate different immune mechanisms make it a promising candidate for combination therapy, as it can potentially enhance the efficacy of other treatments. Overall, Mosunetuzumab Biosimilar has shown great promise as a potential therapeutic option for the treatment of B cell malignancies. Its unique structure, targeting multiple proteins, and ability to activate different immune mechanisms make it a versatile and potentially effective treatment option. Further research and clinical trials will be needed to fully understand its potential and determine its safety and efficacy in treating these diseases.